Keyphrases
Polyneuropathy
91%
Sensorimotor Polyneuropathy
33%
Vasculitic Neuropathy
33%
Neurofilament Light (NF-L)
33%
Prognostic Value
33%
3-year Follow-up
33%
Hypokalemic Periodic Paralysis
33%
Strength Training
33%
Functional Outcome
33%
Treatment Delay
33%
SLC25A46
33%
Scoping Review
33%
Misinterpretation
33%
Optic Atrophy
33%
Novel Variants
33%
Functional Strength
33%
Paralysis
27%
Disease Progression
14%
Charcot-Marie-Tooth
12%
Slowly Progressive
11%
Muscle Strength
11%
Periodic Paralysis
11%
Fat Replacement
11%
Muscle Weakness
11%
CACNA1S
11%
Plexopathy
8%
Differential Diagnosis
8%
Disease Mechanisms
8%
Disease Spectrum
8%
Mitochondrial Proteins
8%
Mitochondrial Dynamics
8%
Neurological Syndrome
8%
Whole Exome Sequencing
8%
Neurological Examination
8%
Neurological Symptoms
8%
Iraq
8%
Nerve Conduction Studies
8%
Rituximab
8%
Diagnostic Potential
8%
Neuropathy
8%
Nerve Damage
8%
Prednisolone
8%
Biallelic Variants
8%
Unknown Etiology
8%
Progressive Neuropathy
8%
Chronic Inflammatory Demyelinating Polyneuropathy
6%
Protein Level
6%
Diabetic Neuropathy
6%
Embase
6%
Cochrane Library
6%
Medicine and Dentistry
Polyneuropathy
100%
Optic Nerve Atrophy
33%
Systematic Review
33%
Resistance Training
33%
Neurofilament
33%
Hypokalemic Periodic Paralysis
33%
Neuropathy
33%
Paralysis
27%
Weakness
16%
Muscle Strength
16%
Disease Exacerbation
14%
Neurologic Disease
13%
Disease
13%
Periodic Paralysis
11%
Muscle Weakness
11%
Diagnosis
9%
Biological Marker
9%
Neurologic Examination
6%
Exome Sequencing
6%
Nerve Conduction Study
6%
Mitochondrial Protein
6%
Mitochondrial Dynamics
6%
Chronic Inflammatory Demyelinating Polyneuropathy
6%
Diabetic Neuropathy
6%
Functional Disease
6%
Channelopathy
5%
Myopathy
5%
Plexopathy
5%
Nerve Injury
5%
Prednisolone
5%
Differential Diagnosis
5%
Rituximab
5%
Immunosuppressant
5%
